{"id":"W2397893479","doi":"10.1158/1538-7445.sabcs15-ot3-01-01","title":"Abstract OT3-01-01: HERMIONE: A phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1)","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Pertuzumab; Trastuzumab; Medicine; Anthracycline; Vinorelbine; Internal medicine; Oncology; Clinical endpoint; Metastatic breast cancer; Capecitabine; Hazard ratio; Breast cancer; Interim analysis; Docetaxel; Chemotherapy; Cancer; Randomized controlled trial; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001738371,0.00206492,0.001961561,0.0004253064,0.0003752153,0.001196734,0.001131417,0.001932213,0.01121344],"category_scores_gemma":[0.001272789,0.0006057656,0.00153665,0.0003725663,0.001454416,0.001305375,0.0004461656,0.003304592,0.001510151],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009098727,"about_ca_system_score_gemma":0.001553954,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001102702,"about_ca_topic_score_gemma":0.002868548,"domain_scores_codex":[0.9995765,0.0002054823,0.00001870102,0.00009341917,0.00002468466,0.00008119557],"domain_scores_gemma":[0.9991974,0.0001600521,0.0001710933,0.00005305199,0.00003621386,0.0003822636],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9734073,0.01032197,0.0003978785,0.0003592408,0.0003349003,0.00004763056,0.00005416317,0.000334517,0.00393471,0.0001969302,0.001576928,0.009033866],"study_design_scores_gemma":[0.9298307,0.06798671,0.0007700924,0.00002183977,0.0001278707,0.00002358035,0.00001583052,0.0001948946,0.0003098923,0.00009158086,0.0006171335,0.000009747547],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9808038,0.002341295,0.0004823501,0.001157305,0.0006457162,0.006670841,0.002943278,0.0002045953,0.004750761],"genre_scores_gemma":[0.9697005,0.001956417,0.002179501,0.002276819,0.0007201065,0.008510854,0.00419261,0.00004939409,0.01041396],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01121344,"threshold_uncertainty_score":0.03751266,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05709300248088015,"score_gpt":0.426296222629143,"score_spread":0.3692032201482628,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}